Recita 10 mg (Tablet)

Unit Price: ৳ 10.00 (3 x 10: ৳ 300.00)

Strip Price: ৳ 100.00

Medicine Details

Category	Details
Generic	Escitalopram oxalate
Company	Goodman pharmaceuticals ltd
Also available as	Recita 5 mg tablet

Selective serotonin reuptake inhibitor (SSRI)
Pure S-enantiomer of the racemic bicyclic phthalate derivative citalopram
At least 100 fold more potent than the R-enantiomer
No or very low affinity for serotonergic or other receptors including alpha- and beta-adrenergic Dopamine, Histamine, Muscarinic and benzodiazepine receptors

SSRI or related antidepressants should not be started until 2 weeks after stopping an MAOI
An MAOI should not be started until at least a week after an SSRI or related antidepressant has been stopped

Contraindicated in patients with known hypersensitivity to Escitalopram or Citalopram or any of the inactive ingredients
Concomitant use of escitalopram in patients taking monoamine oxidase/pimozide is contraindicated

Less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants
Gastrointestinal effects include nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, constipation
Hypersensitivity reactions including rash, urticaria, angioedema, anaphylaxis
Other side-effects include dry mouth, nervousness, anxiety, headache, insomnia, tremor, dizziness, asthenia, hallucinations, drowsiness, convulsions, galactorrhoea, sexual dysfunction, urinary retention, sweating, hypomania or mania, movement disorders and dyskinesias, visual disturbances

Excreted in human breast milk
Physician should carefully consider the potential risks and benefits of treatment when treating a pregnant woman with Escitalopram during the third trimester
Decision whether to continue or discontinue either nursing or Escitalopram therapy should take into account the risk of citalopram exposure for the infant and the benefits Escitalopram treatment for the mother

Use with caution in patients with epilepsy, concurrent electroconvulsive therapy, history of mania, cardiac disease, diabetes mellitus, angle-closure glaucoma, concomitant use of drugs that increase risk of bleeding, history of bleeding disorders, hepatic and renal impairment

Elderly patients (>65 years of age)
Children and adolescents (<18 years)
Dosage adjustment in reduced renal function and hepatic function
Poor metabolizers of CYP2C19
Gradual reduction of dose over a period of at least one to two weeks when stopping treatment

Symptoms include dizziness, tremor, agitation, serotonin syndrome, convulsion, coma, nausea/vomiting, hypotension, tachycardia, QT interval prolongation, arrhythmia, hypokalaemia, hyponatremia
No specific antidote
Establish and maintain an airway, ensure adequate oxygenation and respiratory function
Gastric lavage and the use of activated charcoal should be considered